Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.

2.50
Hdl Handle:
http://hdl.handle.net/10541/75867
Title:
Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.
Authors:
Shnyder, Steven D; Hasan, Jurjees; Cooper, Phillip A; Pilarinou, E; Jubb, E; Jayson, Gordon C ( 0000-0002-8515-8944 ) ; Bibby, Michael
Abstract:
BACKGROUND: Previous studies have shown extensive vascularisation surrounding subcutaneously implanted fibres when the duration of the US National Cancer Institute (NCI) hollow fibre assay was prolonged. MATERIALS AND METHODS: The feasibility of adapting the NCI assay for evaluating agents targeting the tumour vasculature was investigated in vitro and in vivo. Finally, in the optimised assay, changes in neovasculature formation around the fibres following treatment with the anti-vascular agent paclitaxel were quantified by immunohistochemistry. RESULTS: Correlations between cell number seeded, time in culture and vascular endothelial growth factor (VEGF) secretion were seen. In vivo studies showed that transplanting single rather than 3 fibres at a site reduced inflammation, reducing the length of the fibre transplanted, as did without any significant loss in cell growth over 21 days. A statistically significant reduction in neovascularisation surrounding the fibres was seen accompanying paclitaxel treatment. CONCLUSION: Modifications made here to the NCI hollow fibre assay demonstrate its potential for analysing anti-tumour vasculature agents.
Affiliation:
Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford, UK. S.D.Shnyder@Bradford.ac.uk
Citation:
Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature., 25 (3B):1889-94 Anticancer Res.
Journal:
Anticancer Research
Issue Date:
29-Jul-2009
URI:
http://hdl.handle.net/10541/75867
PubMed ID:
16158922
Type:
Article
Language:
en
ISSN:
0250-7005
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorShnyder, Steven D-
dc.contributor.authorHasan, Jurjees-
dc.contributor.authorCooper, Phillip A-
dc.contributor.authorPilarinou, E-
dc.contributor.authorJubb, E-
dc.contributor.authorJayson, Gordon C-
dc.contributor.authorBibby, Michael-
dc.date.accessioned2009-07-29T14:22:01Z-
dc.date.available2009-07-29T14:22:01Z-
dc.date.issued2009-07-29T14:22:01Z-
dc.identifier.citationDevelopment of a modified hollow fibre assay for studying agents targeting the tumour neovasculature., 25 (3B):1889-94 Anticancer Res.en
dc.identifier.issn0250-7005-
dc.identifier.pmid16158922-
dc.identifier.urihttp://hdl.handle.net/10541/75867-
dc.description.abstractBACKGROUND: Previous studies have shown extensive vascularisation surrounding subcutaneously implanted fibres when the duration of the US National Cancer Institute (NCI) hollow fibre assay was prolonged. MATERIALS AND METHODS: The feasibility of adapting the NCI assay for evaluating agents targeting the tumour vasculature was investigated in vitro and in vivo. Finally, in the optimised assay, changes in neovasculature formation around the fibres following treatment with the anti-vascular agent paclitaxel were quantified by immunohistochemistry. RESULTS: Correlations between cell number seeded, time in culture and vascular endothelial growth factor (VEGF) secretion were seen. In vivo studies showed that transplanting single rather than 3 fibres at a site reduced inflammation, reducing the length of the fibre transplanted, as did without any significant loss in cell growth over 21 days. A statistically significant reduction in neovascularisation surrounding the fibres was seen accompanying paclitaxel treatment. CONCLUSION: Modifications made here to the NCI hollow fibre assay demonstrate its potential for analysing anti-tumour vasculature agents.en
dc.language.isoenen
dc.subjectCell Line Tumouren
dc.subjectLung Canceren
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshAnimals-
dc.subject.meshAntineoplastic Agents, Phytogenic-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshCell Growth Processes-
dc.subject.meshCell Line, Tumor-
dc.subject.meshDrug Screening Assays, Antitumor-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMice-
dc.subject.meshMice, Nude-
dc.subject.meshNeovascularization, Pathologic-
dc.subject.meshPaclitaxel-
dc.subject.meshVascular Endothelial Growth Factor A-
dc.subject.meshXenograft Model Antitumor Assays-
dc.titleDevelopment of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.en
dc.typeArticleen
dc.contributor.departmentCancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford, UK. S.D.Shnyder@Bradford.ac.uken
dc.identifier.journalAnticancer Researchen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.